Scott Davies Sells 615 Shares of Illumina (NASDAQ:ILMN) Stock

Illumina, Inc. (NASDAQ:ILMN) insider Scott Davies sold 615 shares of Illumina stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $160.00, for a total transaction of $98,400.00. Following the sale, the insider directly owned 21,568 shares of the company’s stock, valued at $3,450,880. This represents a 2.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Stock Down 1.1%

Shares of NASDAQ ILMN opened at $162.55 on Wednesday. Illumina, Inc. has a 52-week low of $78.79 and a 52-week high of $165.97. The firm has a market capitalization of $24.59 billion, a price-to-earnings ratio of 29.55, a PEG ratio of 2.72 and a beta of 1.50. The stock has a 50 day moving average price of $134.48 and a 200 day moving average price of $132.39. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.05 by $0.10. The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.Illumina’s quarterly revenue was up 4.8% on a year-over-year basis. During the same period last year, the business posted $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Sell-side analysts expect that Illumina, Inc. will post 5.2 earnings per share for the current year.

Institutional Investors Weigh In On Illumina

Institutional investors have recently added to or reduced their stakes in the stock. Glenmede Trust Co. NA lifted its position in shares of Illumina by 6.5% during the first quarter. Glenmede Trust Co. NA now owns 2,288 shares of the life sciences company’s stock valued at $282,000 after buying an additional 140 shares during the last quarter. Groupama Asset Managment grew its position in shares of Illumina by 3.7% in the 1st quarter. Groupama Asset Managment now owns 9,545 shares of the life sciences company’s stock worth $1,177,000 after buying an additional 340 shares during the last quarter. Janus Henderson Group PLC grew its position in shares of Illumina by 1.4% in the 1st quarter. Janus Henderson Group PLC now owns 2,100,638 shares of the life sciences company’s stock worth $258,924,000 after buying an additional 29,094 shares during the last quarter. Bull Harbor Capital LLC bought a new position in shares of Illumina during the 1st quarter worth approximately $1,413,000. Finally, Arkadios Wealth Advisors lifted its position in Illumina by 1.6% during the first quarter. Arkadios Wealth Advisors now owns 8,001 shares of the life sciences company’s stock valued at $986,000 after acquiring an additional 124 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Key Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Guggenheim raised its price target on Illumina to $180 from $170 and reiterated a Buy rating, signaling confidence in further upside for the genomics leader. Benzinga article
• Positive Sentiment: Integrated DNA Technologies said its oncology research workflows are being optimized on Illumina software, a small but constructive development that could reinforce Illumina’s ecosystem in cancer research and data analysis. Business Wire article
• Neutral Sentiment: Recent news about genomics and synthetic biology stocks being in the spotlight highlights ongoing investor interest in the sector, though the coverage did not specifically point to Illumina as a named leader in those articles. Yahoo Finance article
• Neutral Sentiment: Illumina reported strong prior-quarter results, beating EPS and revenue estimates and maintaining FY2026 guidance, which continues to underpin the stock’s fundamental case. MarketBeat article
• Negative Sentiment: Director Keith A. Meister sold a large block of shares in multiple transactions, and CAO Scott D. Ericksen also sold stock. While the sales were disclosed and one was under a 10b5-1 plan, the size and frequency of insider selling can weigh on investor sentiment. SEC filing

Analyst Ratings Changes

ILMN has been the subject of a number of research reports. Piper Sandler lowered their price objective on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a research note on Monday, February 9th. Daiwa Securities Group raised shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price on the stock in a research report on Thursday, May 14th. Citigroup boosted their price target on shares of Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a report on Monday, May 4th. Guggenheim upped their price target on shares of Illumina from $170.00 to $180.00 and gave the stock a “buy” rating in a research report on Monday. Finally, Royal Bank Of Canada initiated coverage on shares of Illumina in a research note on Thursday, May 14th. They set an “outperform” rating and a $170.00 price objective on the stock. Seven research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $138.38.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.